RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.16.20195693
DO 10.1101/2020.09.16.20195693
A1 Fabrice Carrat
A1 Xavier de Lamballerie
A1 Delphine Rahib
A1 Hélène Blanché
A1 Nathanael Lapidus
A1 Fanny Artaud
A1 Sofiane Kab
A1 Adeline Renuy
A1 Fabien Szabo de Edelenyi
A1 Laurence Meyer
A1 Nathalie Lydié
A1 Marie-Aline Charles
A1 Pierre-Yves Ancel
A1 Florence Jusot
A1 Alexandra Rouquette
A1 Stéphane Priet
A1 Paola Mariela Saba Villarroel
A1 Toscane Fourié
A1 Clovis Lusivika-Nzinga
A1 Jerome Nicol
A1 Stephane Legot
A1 Nathalie Druesne-Pecollo
A1 Younes Esseddik
A1 Cindy Lai
A1 Jean-Marie Gagliolo
A1 Jean-François Deleuze
A1 Nathalie Bajos
A1 Gianluca Severi
A1 Mathilde Touvier
A1 Marie Zins
A1 for the SAPRIS and SAPRIS-SERO study groups
YR 2020
UL http://medrxiv.org/content/early/2020/09/18/2020.09.16.20195693.abstract
AB Background To estimate the seroprevalence of SARS-CoV-2 infection in May-June 2020 after the lockdown in adults living in three regions in France and to identify the associated risk factors.Methods Participants in a survey on COVID-19 from an existing consortium of three general adult population cohorts living in the Ile-de-France (IDF) or Grand Est (GE) - two regions with high rate of COVID-19, or in the Nouvelle-Aquitaine (NA) – with a low rate, were asked to take a dried-blood spot (DBS) for anti-SARS-CoV-2 antibodies assessment.The primary outcome was a positive anti-SARS-CoV-2 ELISA IgG result against the spike protein of the virus (ELISA-S). The secondary outcomes were a positive ELISA IgG against the nucleocapsid protein (ELISA-NP), anti-SARS-CoV-2 neutralizing antibodies titers ≥40 (SN), and predicted positivity obtained from a multiple imputation model (MI). Prevalence estimates were adjusted using sampling weights and post-stratification methods.Findings Between May 4, 2020 and June 23, 2020, 16,000 participants were asked to provide DBS, and 14,628 were included in the analysis, 983 with a positive ELISA-S, 511 with a positive ELISA-NP, 424 with SN≥40 and 941±31 with a positive MI. Adjusted estimates of seroprevalence (positive ELISA-S) were 10.0% (95%CI 9.1%;10.9%) in IDF, 9.0% (95%CI 7.7%; 10.2%) in GE and 3.1% (95%CI 2.4%; 3.7%), in NA. The adjusted prevalence of positive ELISA-NP, SN and MI were 5.7%, 5.0% and 10.0% in IDF, 6.0%, 4.3% and 8.6% in GE, and 0.6%, 1.3% and 2.5% in NA, respectively. A higher seroprevalence was observed in younger participants and when at least one child or adolescent lived in the same household. A lower seroprevalence was observed in smokers compared to non-smokers.Interpretation At the end of the lockdown the prevalence of anti-SARS-CoV-2 IgG or neutralizing antibodies remained low in the French adult population, even in regions with high reported rates of COVID-19.Competing Interest StatementProf Fabrice Carrat reports personal fees from Imaxio and Sanofi, outside the submitted work. All other authors declare no competing interestClinical Trial#NCT04392388Funding StatementThis study was funded by ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Medicale (#20RR052-00), Inserm (Institut National de la Sante et de la Recherche Medicale, #C20-26).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SAPRIS survey was approved by the Inserm ethics committee (approval #20-672 dated March 30, 2020). The SAPRIS-SERO study was approved by the Sud-Mediterranee III ethics committee (approval #20.04.22.74247) and electronic informed consent was obtained from all participants for DBS testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during the current study are available from the corresponding author on reasonable request